Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centene Corp (CNC) vs GSK plc (GSK) Price & Performance

Centene CorpTrade

Price performance (Past 24H)

Key statistics

Centene Corp vs GSK plc — how do they compare? Centene Corp trades at $66.57 (market cap $32.05B), while GSK plc trades at $50.36 (market cap $102.60B). The key difference: GSK plc is far larger — about 3.2× Centene Corp's market cap, and GSK plc pays a 3.57% dividend while Centene Corp pays none. Which is the better fit depends on your goals.

CNCGSK
Market Cap
$32.05B$102.60B
Sector
HealthHealth
52-Week High
$68.72$61.18
52-Week Low
$26.17$38.22
Enterprise Value
$21.10B$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Centene Corp

Centene (CNC) trades at $66.94, up 0.57% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates with EPS of $2.51 versus $1.09 expected, driven by margin recovery and cost control. The stock shows attractive valuation metrics, including a P/E of 8.06 and P/S of 0.16, while revenue growth remains robust at $194.78B in 2025.

Outlook is positive with a consensus price target of $71.00, though risks include Medicaid membership volatility and net income margin pressure. The company's raised 2026 EPS guidance and operational cash flow strength support upside potential, but investors should weigh competitive and regulatory challenges in the managed care sector.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK